Tumor Type-Agnostic Treatment and the Future of Cancer Therapy

Raez, Luis E.; Santos, Edgardo S.

doi:10.1007/s11523-018-0593-y

Cited by 7 publications

(1 citation statement)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For decades, solid tumors have traditionally been classified according to histological findings in affected organs or tissues. The rationale behind this thinking was that organ or tissue type is linked to the biological behavior of the tumor; consequently, most cancer therapies have been developed according to this classification [1]. However, this has not been the case in many situations, and the past more than 30 years of developments in molecular medicine have taught us that cancer is a group of heterogeneous diseases driven by complex molecular mechanisms.…”

Section: Introductionmentioning

confidence: 99%

The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug

Jørgensen

2023

Oncology

View full text Add to dashboard Cite

Background: Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue-agnostic drug refers to a drug that targets a specific molecular alteration across multiple cancer types, as defined by organ, tissue, or tumor type. Summary: Over the last 6 years, the FDA has approved seven tissue-agnostic drugs, and more are anticipated in the future. One promising candidate for a tissue-agnostic classification is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Currently, T-DXd is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive and HER2-low breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and non-small cell lung cancer with activating HER2 mutations. Ongoing clinical research is exploring the potential of T-DXd in various solid tumors that harbor specific HER2 molecular alterations, and encouraging results, including the interim data from the DESTINY-PanTumor02 trial, have been published, which suggest a tissue-agnostic potential. Key Messages: Published phase I data as well as the interim results from the phase II DESTINY-PanTumor02 trial indicates that patients with different HER2-positive advanced solid tumors may benefit from treatment with T-DXd. Based on the currently available data, it seems likely that T-DXd possesses pantumor activity. However, different clinical trials are ongoing, and it will be necessary to see the results from these trials before drawing a final conclusion. When discussing tissue-agnostic potential, it is important to add that for most of the patients enrolled in the DESTINY-PanTumor02 and other trials, few treatment alternatives seem to exist, and T-DXd might be able to cover an unmet medical need.

show abstract

Section: Introductionmentioning

confidence: 99%